Anti-tumor activity of Shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway

Acquired resistance of afatinib is a significant challenge for non-small cell lung cancer (NSCLC) therapy and the mechanisms remain unclear. Aberrant activation of epidermal growth factor receptor (EGFR)-dependent downstream pathways, especially phosphatidylinositol-3-kinases/protein kinase B (PI3K/...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Baiying, Yuan, Zuguo, Jiang, Jin, Rao, Yuanquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294622/
https://www.ncbi.nlm.nih.gov/pubmed/30420490
http://dx.doi.org/10.1042/BSR20181693

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294622/
https://www.ncbi.nlm.nih.gov/pubmed/30420490
http://dx.doi.org/10.1042/BSR20181693

Ejemplares similares